Lion’s mane, or Hericium erinaceus, is an edible mushroom studied in humans mainly for Cognitive Health, Neurological Health, Mental Health, Stress, Sleep, and metabolic-context outcomes, with clinical evidence still limited by small trials and non-equivalent formulations. (Review)
Human studies of lion’s mane include single-dose acute testing and repeated-use interventions lasting 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 49 weeks. The most developed human research area is Cognitive Health, including mild cognitive impairment, older-adult cognition, and mild Alzheimer’s disease. (Research) (Research) Interpretation depends strongly on formulation, because 3 g/day whole mushroom powder, 3 g 10:1 fruiting-body extract, 10 g/day muffin-delivered mushroom material, and three 350 mg capsules/day of erinacine A–enriched mycelium are different research exposures. (Research) (Research) (Research) (Research)
Ingredient Identity
- Official name(s): Lion’s mane mushroom; Hericium erinaceus. (Review)
- Synonyms: Yamabushitake, monkey head mushroom, bearded tooth fungus. (Review)
- Classification: Edible basidiomycete mushroom containing polysaccharides, terpenoids, and other fungal metabolites. (Review)
- CAS number: Not applicable to whole lion’s mane mushroom because it is a biological material rather than one purified chemical compound. (Review)
- Endogenous vs exogenous: Exogenous; humans consume lion’s mane from food or supplemental preparations and do not synthesize the mushroom endogenously. (Review)
Ingredient Snapshot
- Classification: Lion’s mane is an edible mushroom studied as whole fruiting-body powder, fruiting-body extract, food-format mushroom material, and mycelium-derived preparations. (Review)
- Endogenous vs exogenous status: Lion’s mane is an external dietary or supplement exposure, not a compound naturally produced by the human body. (Review)
- Primary human research domains: Human studies focus most often on Cognitive Health, Neurological Health, Mental Health, Stress, Sleep, and metabolic-context outcomes. (Review)
- Common study formats: Published human studies include randomized placebo-controlled trials, pilot interventions, acute crossover studies, food-format studies, and broader observational mushroom-intake research. (Review)
- Studied exposure range: Human research examples include 1 g acute Nordic-grown lion’s mane, 1.8 g/day for 28 days, 3 g/day whole Yamabushitake powder for 16 weeks, 3 g single-dose 10:1 fruiting-body extract, 10 g/day muffin-delivered mushroom material for 4 weeks, and three 350 mg capsules/day of erinacine A–enriched mycelium for 49 weeks. (Research) (Research) (Research) (Research) (Research) (Research)
- Human study duration range: Human studies range from single-dose acute testing to 49 weeks of repeated intake. (Research) (Research)
- Pharmacokinetic characterization status: Formal human pharmacokinetic values such as Tmax and half-life are not established for lion’s mane as a whole mushroom material, and outcome studies provide timing anchors rather than true pharmacokinetic curves. (Research)
- Regulatory context: In the United States, FDA regulates dietary supplements differently from drugs and does not approve dietary supplements for safety or effectiveness before marketing. (FDA) (FDA)
- Evidence maturity: The overall evidence is Limited / Mixed because several small human studies exist, but results vary by population, formulation, dose, duration, and endpoint. (Review)
Introduction
Lion’s mane is a white, spine-forming edible mushroom that can be consumed as food or processed into powder, extract, or mycelium-based preparations. Reviews describe lion’s mane as a source of multiple compound classes, including polysaccharides and terpenoid metabolites, but the composition differs between fruiting body, mycelium, and extract preparations. (Review)
Readers commonly search for lion’s mane because human studies have examined cognitive scores, mood questionnaires, stress measures, sleep-related outcomes, and dementia-related outcomes. Reviews describe this research area as active but still limited, especially because studies use small samples and materially different preparations. (Review) (Review)
This article is informational only, describes lion’s mane as a biochemical and dietary mushroom material studied in human research, and does not provide medical or dosing advice. (FDA)
Quick Summary
- Lion’s mane is an edible mushroom studied in humans mainly for Cognitive Health, Neurological Health, Mental Health, Stress, Sleep, and metabolic-context outcomes. (Review)
- The most developed human research area is Cognitive Health, with studies in mild cognitive impairment, older adults, and mild Alzheimer’s disease. (Research) (Research)
- Human study durations range from single acute dosing to 49 weeks, with repeated-use studies commonly lasting 4, 8, 12, 16, or 49 weeks. (Research) (Research) (Research) (Research)
- Studied exposures are not interchangeable: 3 g/day Yamabushitake powder, 3 g 10:1 fruiting-body extract, 10 g/day muffin-delivered mushroom material, and three 350 mg capsules/day erinacine A–enriched mycelium represent different forms. (Research) (Research) (Research) (Research)
- Acute studies provide outcome-timing anchors such as 60-minute or 90-minute post-dose testing, but they do not establish a formal human Tmax for lion’s mane constituents. (Research) (Research)
- Safety evidence in humans is limited; trials generally report tolerability, while medical safety summaries note mild gastrointestinal complaints and rare hypersensitivity-type concerns. (Review)
- U.S. dietary supplements containing lion’s mane are not FDA-approved as treatments or cures before marketing. (FDA)
Human Research Findings by Condition
Cognitive Health
Human research on Cognitive Health includes randomized or controlled studies in mild cognitive impairment, older-adult cognition, healthy-adult cognition, and mild Alzheimer’s disease. The strongest signal appears in older or cognitively impaired populations, while healthy-adult findings are more mixed. (Research) (Review)
Key human study
Dose studied: 3 g/day Yamabushitake / lion’s mane powder
Population: Japanese adults aged 50–80 with mild cognitive impairment
Duration: 16 weeks, plus follow-up after stopping
Researchers studied 3 g/day Yamabushitake powder in adults with mild cognitive impairment. Cognitive-function scores were significantly higher in the lion’s mane group at weeks 8, 12, and 16, and scores declined after intake stopped. (Research)
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)
Additional human study
Dose studied: Oral Hericium erinaceus product; exact product details should not be generalized across all powders or extracts
Population: Adults in a cognitive-function trial
Duration: 12 weeks
A randomized placebo-controlled trial evaluated oral H. erinaceus and measured MMSE, Benton visual retention, and verbal paired-associate learning outcomes. MMSE improved, while the other cognitive measures were less clearly positive. (Research)
Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)
Neurological Health
Neurological Health research is centered on mild Alzheimer’s disease and cognitive-decline contexts. The most specific human evidence uses erinacine A–enriched mycelium, which is not equivalent to whole fruiting-body powder or generic fruiting-body extract. (Research) (Review)
Key human study
Dose studied: Three 350 mg capsules/day of erinacine A–enriched H. erinaceus mycelium, standardized to 5 mg/g erinacine A
Population: People with mild Alzheimer’s disease
Duration: 49 weeks, after a 3-week screening period
Researchers studied a standardized erinacine A–enriched mycelium product in people with mild Alzheimer’s disease. The intervention group showed higher cognitive and functional scores than placebo, but the finding applies to this enriched mycelium material rather than to all lion’s mane products. (Research)
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Limited
Study source: (Research)
Additional human study
Dose studied: Erinacine A–enriched mycelium in a mild Alzheimer’s disease research context
Population: People with mild Alzheimer’s disease
Duration: Study-specific follow-up context
Additional human research examined erinacine A–enriched H. erinaceus mycelium in relation to Alzheimer’s-related outcomes. This evidence remains formulation-specific and should not be transferred to fruiting-body powder without direct comparative data. (Research)
Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)
Mental Health
Human Mental Health research has examined depression-related scores, anxiety-related scores, and related subjective measures. The evidence is exploratory because the studies are small, short, and often overlap with sleep, stress, or diet-context outcomes. (Research) (Research)
Key human study
Dose studied: Lion’s mane powder incorporated into cookies
Population: 30 women
Duration: 4 weeks
A randomized trial in women evaluated lion’s mane intake using questionnaires related to menopause, depression, sleep quality, and indefinite complaints. Depression- and anxiety-related scores decreased in the lion’s mane group, but the sample was small and the study was short. (Research)
Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)
Additional human study
Dose studied: Lion’s mane supplementation in a low-calorie diet setting
Population: Adults with overweight or obesity
Duration: 8 weeks
A clinical study in adults with overweight or obesity assessed depression, anxiety, sleep, and binge-eating measures after 8 weeks of supplementation. Several psychological and sleep-related measures improved, but the low-calorie diet context makes ingredient-specific interpretation difficult. (Research)
Result: Human clinical study reported a modest improvement
Evidence strength: Emerging
Study source: (Research)
Stress
Stress research in humans is mostly represented by small healthy-adult trials. The clearest modern study used 1.8 g/day for 28 days and reported a subjective-stress signal, while also reporting null or limited negative findings. (Research)
Key human study
Dose studied: 1.8 g/day Hericium erinaceus
Population: Healthy adults aged 18–45
Duration: Acute testing plus 28 days
A double-blind pilot trial tested acute and repeated lion’s mane intake in healthy adults. The study reported faster performance on one Stroop-task measure after acute intake and a trend toward reduced subjective stress after 28 days, but the authors cautioned that the sample was small and findings were not uniformly positive. (Research)
Result: Human clinical studies reported mixed findings
Evidence strength: Emerging
Study source: (Research)
Sleep
Sleep has been studied mainly as a secondary or overlapping outcome rather than as a dedicated sleep-disorder indication. Existing evidence includes a 4-week women’s trial and an 8-week study in adults with overweight or obesity, but neither establishes lion’s mane as a sleep-specific intervention. (Research) (Research)
Key human study
Dose studied: Lion’s mane supplementation in a low-calorie diet program
Population: Adults with overweight or obesity
Duration: 8 weeks
Researchers assessed sleep along with depression, anxiety, and binge-eating outcomes. Sleep-related measures improved, but the study context included a low-calorie diet and multiple psychological endpoints. (Research)
Result: Human clinical study reported a modest improvement
Evidence strength: Emerging
Study source: (Research)
Additional human study
Dose studied: Lion’s mane powder in food format
Population: 30 women
Duration: 4 weeks
A randomized trial in women included sleep quality among several assessed outcomes. The study is best interpreted as exploratory because it was small and not designed as a dedicated sleep trial. (Research)
Result: Human evidence remains limited or inconclusive
Evidence strength: Limited
Study source: (Research)
Obesity and Weight Regulation
Obesity and Weight Regulation evidence does not establish lion’s mane as a weight-loss intervention. Human studies in this area mostly use adults with overweight or obesity as a population context for mood, sleep, binge-eating, or metabolic-flexibility outcomes. (Research) (Research)
Key human study
Dose studied: Lion’s mane supplementation in a low-calorie diet setting
Population: Adults with overweight or obesity
Duration: 8 weeks
Researchers studied lion’s mane during a low-calorie diet program and measured depression, anxiety, sleep, and binge-eating outcomes. The findings are relevant to behavioral and psychological outcomes in an overweight/obesity context, not to direct body-weight effects. (Research)
Result: Human clinical study reported a modest improvement
Evidence strength: Emerging
Study source: (Research)
Additional human study
Dose studied: 10 g/day Hericium erinaceus delivered in muffins
Population: College-age adults
Duration: 4 weeks
A 4-week study tested 10 g/day muffin-delivered lion’s mane and measured metabolic flexibility and cognition. The study found no clear effect on metabolic flexibility or cognitive outcomes in this cohort. (Research)
Result: Human clinical study reported no clear effect
Evidence strength: Limited
Study source: (Research)
Dosage & Study Snapshot (Research Context)
Human lion’s mane dose interpretation requires both the amount and the material type. A gram amount of whole mushroom powder is not equivalent to the same gram amount of a concentrated extract, and a mycelium product standardized to erinacine A is not interchangeable with fruiting-body powder. (Research) (Research) (Research)
| Studied exposure | Material type | Delivery format | Population/context | Duration | Research result |
|---|---|---|---|---|---|
| More than 2 portions/week mushroom intake | Dietary mushroom intake; not lion’s-mane-specific | Diet | Adults ≥60 in Singapore | Observational | Associated with lower odds of mild cognitive impairment |
| 1 g acute Nordic-grown lion’s mane | Study-specific lion’s mane material | Oral acute exposure | Healthy adults | Single-dose acute testing | Acute cognition comparison versus guayusa and placebo |
| 1.8 g/day | H. erinaceus supplement material | Oral supplement | Healthy adults aged 18–45 | Acute + 28 days | Mixed findings; task-specific speed and stress signals |
| 3 g/day | Yamabushitake / whole lion’s mane powder | Oral powder | Adults with mild cognitive impairment | 16 weeks | Cognitive scores improved during intake |
| 3 g single dose | 10:1 fruiting-body extract | Oral extract | Healthy adults 18–35 | Acute testing | No significant overall cognition or mood improvement |
| Three 350 mg capsules/day | Erinacine A–enriched mycelium, 5 mg/g erinacine A | Capsules | Mild Alzheimer’s disease | 49 weeks | Better cognitive and functional scores versus placebo |
| 10 g/day | Whole-material lion’s mane in muffins | Food matrix | College-age adults | 4 weeks | No clear metabolic-flexibility or cognitive effect |
More than 2 portions/week dietary mushroom intake:
This exposure comes from observational dietary research on mushroom intake, not a lion’s-mane-specific intervention. In adults aged 60 and older in Singapore, consuming more than two portions of mushrooms per week was associated with lower odds of mild cognitive impairment. This finding helps frame dietary mushroom research but should not be converted into a lion’s mane supplement dose. (Research)
Result: Observational association
Evidence strength: Observational
Notes / limitations: This is not lion’s-mane-specific and does not identify fruiting-body powder, extract, or mycelium exposure.
1 g Nordic-grown lion’s mane, acute oral exposure:
A randomized crossover study evaluated 1 g of Nordic-grown lion’s mane against guayusa and placebo in an acute cognition setting. The study provides an acute testing model, but the material was study-specific and should not be generalized to all powders or extracts. This dose is useful as a low human research exposure, not as a recommended intake. (Research)
Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: Acute testing does not establish long-term effects.
1.8 g/day Hericium erinaceus, acute plus 28-day exposure:
A pilot randomized trial studied 1.8 g/day in healthy adults aged 18–45 and included both acute testing and 28 days of repeated use. The study reported faster performance on one Stroop-task measure after acute intake and a trend toward reduced subjective stress after 28 days. The findings were mixed because null and limited negative findings were also observed. (Research)
Result: Mixed findings
Evidence strength: Emerging
Notes / limitations: The trial was small and not definitive.
3 g/day Yamabushitake / whole lion’s mane powder:
A randomized trial in mild cognitive impairment used 3 g/day Yamabushitake powder for 16 weeks. Cognitive-function scores improved at weeks 8, 12, and 16, and scores declined after intake stopped. This dose should be interpreted as whole mushroom powder, not as a concentrated extract. (Research)
Result: Statistically significant improvement
Evidence strength: Moderate
Notes / limitations: A 3 g/day whole-powder exposure is not equivalent to 3 g/day extract.
3 g 10:1 fruiting-body extract, single acute exposure:
A 2025 acute randomized crossover trial used 3 g of a 10:1 fruiting-body extract in healthy adults aged 18–35. The trial did not find a significant overall improvement in cognition or mood compared with placebo. The 10:1 extract ratio means the exposure should be separated from whole powder studies. (Research)
Result: Neutral overall findings
Evidence strength: Limited
Notes / limitations: This acute extract study does not answer whether chronic fruiting-body extract changes outcomes.
Three 350 mg capsules/day erinacine A–enriched mycelium:
A mild Alzheimer’s disease trial used three 350 mg capsules/day of erinacine A–enriched H. erinaceus mycelium standardized to 5 mg/g erinacine A. The study lasted 49 weeks after a 3-week screening period. The intervention group showed better cognitive and functional scores than placebo, but this evidence is specific to enriched mycelium. (Research)
Result: Statistically significant improvement
Evidence strength: Limited
Notes / limitations: Mycelium standardized to erinacine A should not be treated as ordinary fruiting-body powder.
10 g/day whole-material food-format lion’s mane in muffins:
A 4-week study used 10 g/day H. erinaceus delivered in muffins in a college-age cohort. Researchers measured metabolic flexibility and cognition and found no clear effect. This exposure is a food-format whole-material study and should not be compared directly with extract capsules. (Research)
Result: No clear effect
Evidence strength: Limited
Notes / limitations: Food matrix, dose, and population may affect interpretation.
Key Takeaways from Human Research
- Cognitive Health is the most developed human research area, with studied durations of 12 weeks, 16 weeks, and 49 weeks across different older-adult or cognitive-impairment contexts. (Research) (Research) (Research)
- Formulation is central: a 3 g/day whole-powder study, a 3 g single-dose 10:1 extract study, and a three 350 mg capsule/day erinacine A–enriched mycelium study should not be merged as one dose category. (Research) (Research) (Research)
- Healthy-adult cognition evidence is mixed, with some acute task-specific signals and at least one acute fruiting-body extract trial showing no significant overall cognition or mood effect. (Research) (Research)
- Mental Health, Stress, and Sleep findings come mainly from 4-week, 8-week, and 28-day studies with small or context-specific designs. (Research) (Research) (Research)
- No validated human Tmax or half-life has been established for lion’s mane as a complex mushroom material in the cited clinical evidence. (Research)
Origin & Natural Occurrence
Lion’s mane is a naturally occurring edible mushroom rather than a single synthesized compound. It is known for a white, hanging, spine-like fruiting body and has been reviewed as both a food mushroom and a source of bioactive fungal metabolites. (Review)
Research preparations may use fruiting body, mycelium, or extracts. Fruiting-body and mycelium materials can differ in compound profile, which is one reason the human evidence should be organized by material type. (Review)
Commercial and research products may appear as powders, extracts, food-format preparations, or mycelium-derived capsules. Human findings should be interpreted according to the exact studied material rather than the common name “lion’s mane” alone. (Review)
How It Behaves in the Body
Lion’s mane behaves as a complex mushroom exposure, not as one isolated molecule. After oral intake, the body encounters a mixture of fungal constituents, and the exact mixture depends on whether the studied material is whole fruiting body, extract, food-format mushroom, or mycelium. (Review)
Mechanistic research often focuses on nerve-support signaling, meaning biological pathways related to nerve-cell maintenance and communication. Reviews describe hericenones and erinacines as important compound groups, with hericenones commonly discussed in relation to fruiting-body research and erinacines commonly discussed in relation to mycelium research. (Review)
Human clinical studies have not yet established a clear dose-response curve linking specific lion’s mane compounds to specific outcomes. This is why findings from 3 g/day Yamabushitake powder, 3 g 10:1 fruiting-body extract, and erinacine A–enriched mycelium should remain separate. (Research) (Research) (Research)
What is reasonably clear is that formulation, population, and duration shape interpretation. What remains unresolved is the human pharmacokinetic profile, including formal Tmax, half-life, bioactive-compound exposure curves, and validated biomarkers of intake. (Research)
Absorption & Delivery Formats
Oral immediate-release: Oral intake is the main route studied in humans. Studied oral formats include capsules, powder in cookies, powder or mushroom material in muffins, whole mushroom powder, fruiting-body extract, and erinacine A–enriched mycelium capsules. (Research) (Research) (Research)
Oral extended-release: Extended-release lion’s mane formats are not established in the cited human evidence. No included study shows that extended-release delivery changes cognitive, mood, sleep, or metabolic outcomes. (Review)
Sublingual: Sublingual lion’s mane delivery is not represented in the cited human clinical evidence. Claims about sublingual absorption would require product-specific human data. (Review)
Transdermal: Transdermal lion’s mane delivery is not represented in the cited human research set. Transdermal exposure should not be assumed to behave like oral powder, extract, or mycelium capsules. (Review)
Injectable / IV: Injectable or IV lion’s mane is not an established dietary-supplement research format in the cited human studies. The human evidence summarized here is based on oral exposure. (Review)
Quick Facts at a Glance
Onset (reported): Human studies provide outcome-timing data, not a validated onset time for all lion’s mane products. One healthy-adult study measured acute cognitive effects and reported a task-specific speed finding at about 60 minutes, while a 2025 acute extract study measured outcomes after a single 3 g 10:1 fruiting-body extract exposure and found no significant overall cognition or mood effect. (Research) (Research)
Time to peak (Tmax): A formal human Tmax for lion’s mane constituents has not been established for whole mushroom powder, fruiting-body extract, or erinacine A–enriched mycelium in the cited trials. The best available timing anchors are post-dose outcome assessments such as 60-minute and 90-minute acute testing windows, which are not the same as pharmacokinetic Tmax. (Research) (Research)
Half-life (t½): No validated human half-life is reported for lion’s mane as a whole mushroom material in the cited clinical evidence. A single half-life would also be difficult to assign to the whole ingredient because lion’s mane contains multiple constituents rather than one active compound. (Review)
Typical duration: Published human studies include single-dose acute testing, 4-week, 8-week, 12-week, 16-week, and 49-week designs. Examples include 4 weeks for mood-related questionnaire outcomes, 8 weeks in adults with overweight or obesity, 16 weeks for Yamabushitake powder in mild cognitive impairment, and 49 weeks for erinacine A–enriched mycelium in mild Alzheimer’s disease. (Research) (Research) (Research) (Research)
Absorption routes studied: Oral intake is the only well-represented human route in the cited clinical evidence. Oral study formats include cookies, muffins, capsules, powder, fruiting-body extract, and erinacine A–enriched mycelium capsules. (Research) (Research) (Research)
Formulation differences: The most important formulation distinctions are fruiting body versus mycelium, whole powder versus extract, food matrix versus capsule, and standardized versus non-standardized material. Concrete examples include 3 g/day Yamabushitake powder, 3 g 10:1 fruiting-body extract, 10 g/day muffin-delivered mushroom material, and three 350 mg capsules/day of mycelium standardized to 5 mg/g erinacine A. (Research) (Research) (Research) (Research)
Variability drivers: Variability is driven by fungal part, extraction ratio, standardization, delivery matrix, population, duration, and endpoint. For example, a 10:1 fruiting-body extract in a healthy-adult acute study cannot be interpreted the same way as erinacine A–enriched mycelium in a 49-week mild Alzheimer’s disease study. (Research) (Research)
Tolerance / adaptation: Repeated-use human studies lasted 4, 8, 12, 16, 28-day, and 49-week periods, but these studies did not establish a formal tolerance or adaptation pattern. The absence of a defined tolerance pattern should not be interpreted as proof that tolerance cannot occur; it means the clinical evidence has not characterized it clearly. (Research) (Research) (Research) (Research)
Evidence strength snapshot: Cognitive Health has the most human study coverage, including 12-week, 16-week, and 49-week studies. Stress, Sleep, Mental Health, and metabolic-context outcomes rely on fewer, smaller, or secondary-outcome studies, so overall evidence remains Limited / Mixed. (Research) (Research) (Research) (Review)
Other Physiological Contexts Studied (If Applicable)
- Dietary mushroom intake and cognition: A Singapore observational study linked higher mushroom intake, defined as more than 2 portions/week, with lower odds of mild cognitive impairment, but the exposure was dietary mushrooms broadly rather than lion’s mane specifically. (Research)
- Microbiota research context: A registered clinical study has examined H. erinaceus in relation to microbiota, cognition, and health parameters, but a trial registry record should be interpreted as study-design information rather than completed efficacy evidence. (ClinicalTrials.gov)
- Biomarker context: The overweight/obesity study examined mood and sleep outcomes alongside BDNF-related biomarkers, but this does not establish BDNF as a validated human response marker for all lion’s mane products. (Research)
Safety, Interactions & Regulation
Human clinical trials generally report tolerability in the studied populations, but the total clinical safety database is small. LiverTox summarizes reported trial adverse events as generally mild gastrointestinal complaints and also notes hypersensitivity-type case concerns. (Review)
The 16-week mild cognitive impairment study reported no adverse effects in laboratory tests during the intervention. This safety observation applies to the studied Yamabushitake powder trial and does not establish long-term safety for every lion’s mane extract or mycelium product. (Research)
Potential interaction categories are not well characterized in controlled human studies. Because lion’s mane products differ by fungal part, extraction ratio, and standardization, interaction claims should be treated as limited unless supported by product-specific clinical data. (Review)
Population cautions are mainly evidence-gap cautions rather than proven contraindications. Pregnant people, people using medications, people with mushroom allergy history, and people with serious medical conditions were not broadly represented across the small clinical trial literature. (Review)
In the United States, dietary supplements are regulated under a framework distinct from drugs. FDA states that dietary supplements are not approved for safety and effectiveness before marketing. (FDA) (FDA)
In the European Union, regulatory status can depend on the exact lion’s mane material. An EU-linked Finnish consultation concluded that a described lion’s mane fruiting-body extract powder was not novel under that consultation context, while an EU-linked Spanish consultation concluded that dehydrated H. erinaceus mycelium powder was a novel food because significant pre-1997 EU consumption history was not established. (EFSA) (EFSA)
Evidence Overview
The human evidence base for lion’s mane is strongest for Cognitive Health and Neurological Health, where published studies include 12-week, 16-week, and 49-week interventions in older adults, mild cognitive impairment, and mild Alzheimer’s disease. Evidence is more limited for Mental Health, Stress, Sleep, and Obesity and Weight Regulation because these areas rely on smaller, shorter, or context-specific studies such as 4-week, 8-week, and 28-day interventions. Confidence is not higher because the literature mixes whole powder, fruiting-body extract, food-format mushroom material, and erinacine A–enriched mycelium. (Research) (Research) (Research) (Review)
Positive studies include the 3 g/day Yamabushitake powder mild cognitive impairment trial and the three 350 mg capsules/day erinacine A–enriched mycelium mild Alzheimer’s disease trial. These studies are important but formulation-specific, so they should not be used to claim equivalent effects for every lion’s mane product. (Research) (Research)
Mixed or neutral studies include healthy-adult work using acute or short-term designs. A 1.8 g/day healthy-adult pilot study reported limited task-specific and subjective-stress signals, while a 3 g 10:1 fruiting-body extract acute trial did not show a significant overall cognition or mood effect. (Research) (Research)
The most important interpretation issue is dose identity rather than dose size alone. A 350 mg mycelium capsule standardized to 5 mg/g erinacine A, a 3 g/day whole mushroom powder, a 3 g 10:1 fruiting-body extract, and 10 g/day muffin-delivered mushroom material represent different exposures. (Research) (Research) (Research) (Research)
Future research would strengthen confidence by using larger samples, standardized material descriptions, verified active-compound profiles, formal pharmacokinetic testing, longer follow-up, and consistent cognitive or mood endpoints. Reviews identify small sample sizes, mixed intervention results, and formulation heterogeneity as major limitations. (Review) (Review)
Evidence Confidence Classification
Limited / Mixed is the overall human evidence classification for lion’s mane because several human studies exist, but they differ substantially in formulation, population, dose, duration, and measured outcomes. (Review)
The evidence is most developed for Cognitive Health and Neurological Health, especially mild cognitive impairment and mild Alzheimer’s disease contexts. (Research) (Research)
The evidence is less mature for Mental Health, Stress, Sleep, and Obesity and Weight Regulation because these areas rely on smaller or more exploratory studies. (Research) (Research) (Research)
Mechanistic research supports biological plausibility, but mechanistic plausibility does not substitute for large, replicated human trials. (Review)
Similar Ingredients & Comparators
Similar supplement-style ingredients:
- Reishi mushroom
- Cordyceps mushroom
- Chaga mushroom
- Turkey tail mushroom
- Shiitake mushroom extracts
- Bacopa monnieri
- Ginkgo biloba
- Citicoline
- Phosphatidylserine
- Rhodiola rosea
Medical / pharma comparator categories:
- Cognitive-symptom medication categories
- Dementia-symptom medication categories
- Antidepressant medication categories
- Sleep-disorder medication categories
- Metabolic-disease medication categories
Combination Context
Lion’s mane + low-calorie diet context:
Lion’s mane was studied for 8 weeks in adults with overweight or obesity during a low-calorie diet program. The study examined depression, anxiety, sleep, and binge-eating outcomes, but the diet context limits interpretation of lion’s mane alone. (Research)
Lion’s mane + food matrix:
Lion’s mane has been delivered in foods such as cookies and muffins in human studies lasting 4 weeks. These formats are useful for food-format exposure research, but they are not equivalent to standardized capsules or concentrated extracts. (Research) (Research)
Lion’s mane + guayusa comparator context:
One acute crossover study compared 1 g Nordic-grown lion’s mane with guayusa and placebo in a cognition context. This study design compared acute cognitive testing signals but did not establish long-term effects. (Research)
FAQ
What is lion’s mane?
Lion’s mane is an edible mushroom known scientifically as Hericium erinaceus. It is studied as a whole mushroom, fruiting-body extract, food-format ingredient, or mycelium-derived preparation rather than as one isolated chemical. (Review) Human research focuses mainly on Cognitive Health, Neurological Health, Mental Health, Stress, Sleep, and metabolic-context outcomes. (Review)
What does human research study lion’s mane for?
Human research studies lion’s mane mostly for Cognitive Health and Neurological Health. Trials have examined mild cognitive impairment, older-adult cognition, mild Alzheimer’s disease, healthy-adult cognitive performance, mood, stress, sleep, and metabolic flexibility. (Research) (Research) Results vary because studies use different formulations and populations. (Review)
What are the best-supported uses?
The best-supported research area is Cognitive Health, especially in mild cognitive impairment and mild Alzheimer’s disease research contexts. A 16-week study used 3 g/day Yamabushitake powder in mild cognitive impairment, and a 49-week study used three 350 mg capsules/day erinacine A–enriched mycelium in mild Alzheimer’s disease. (Research) (Research) These findings are formulation-specific and should not be generalized to all lion’s mane products. (Review)
Where is evidence mixed or limited?
Evidence is mixed or limited in healthy-adult cognition, Mental Health, Stress, Sleep, and metabolic-context outcomes. A 1.8 g/day healthy-adult study reported limited task-specific and stress-related signals, while a 3 g 10:1 fruiting-body extract acute study found no significant overall cognition or mood effect. (Research) (Research) Reviews conclude that larger, better-standardized human trials are needed. (Review)
How quickly does lion’s mane act?
Human studies do not establish one reliable onset time for all lion’s mane products. Acute studies provide practical timing anchors, including 60-minute testing in a 1.8 g study and 90-minute testing in a 3 g 10:1 fruiting-body extract study. (Research) (Research) These are outcome-measure time points, not formal pharmacokinetic Tmax values. (Research)
What affects absorption and variability?
Absorption and outcome variability are affected by material type, fungal part, extraction ratio, standardization, delivery format, population, duration, and endpoint. A 3 g/day whole powder study, a 3 g 10:1 extract study, and a three 350 mg capsule/day enriched-mycelium study are different exposures. (Research) (Research) (Research) Reviews identify formulation heterogeneity as a major limitation in interpreting lion’s mane evidence. (Review)
Is tolerance reported?
A formal tolerance or adaptation pattern has not been established for lion’s mane in human research. Repeated-use studies include 4-week, 8-week, 12-week, 16-week, 28-day, and 49-week designs, but they do not define whether effects diminish, stabilize, or change with continued intake. (Research) (Research) (Research) (Research) Safety summaries describe limited human safety data rather than a full tolerance profile. (Review)
Why do studies disagree?
Studies disagree partly because they use different lion’s mane materials. Whole powder, fruiting-body extract, enriched mycelium, and food-format mushroom may expose participants to different compound profiles. (Research) (Research) (Research) Results also vary because studies enroll different populations and use different cognitive, mood, sleep, or metabolic endpoints. (Review)
What ingredients is lion’s mane commonly combined with and why?
The cited human evidence more often studies lion’s mane in food or diet contexts than in multi-ingredient supplement stacks. Examples include cookie-based delivery for 4 weeks, muffin-based delivery for 4 weeks, and an 8-week low-calorie diet context in adults with overweight or obesity. (Research) (Research) (Research) These designs help study practical intake formats but make ingredient-specific interpretation harder. (Research)
What foods naturally contain lion’s mane?
Lion’s mane itself is a mushroom food. It occurs as the fruiting body of Hericium erinaceus, and human studies have delivered it in food matrices such as cookies and muffins. (Review) (Research) (Research) Broader dietary mushroom research should not be treated as lion’s-mane-specific unless the mushroom species is clearly identified. (Research)
How is lion’s mane regulated?
In the United States, dietary supplements are regulated differently from drugs, and FDA does not approve dietary supplements for safety or effectiveness before marketing. (FDA) (FDA) In the European Union, regulatory status can depend on the exact material, with different consultation outcomes for fruiting-body extract powder and dehydrated mycelium powder. (EFSA) (EFSA)
Resources
Mori et al., Yamabushitake and mild cognitive impairment — PubMed — https://pubmed.ncbi.nlm.nih.gov/18844328/
Saitsu et al., cognitive function trial — PubMed — https://pubmed.ncbi.nlm.nih.gov/31413233/
Li et al., erinacine A–enriched mycelium and mild Alzheimer’s disease — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC7283924/
Nagano et al., mood-related trial — PubMed — https://pubmed.ncbi.nlm.nih.gov/20834180/
Vigna et al., mood and sleep in overweight/obesity — PubMed — https://pubmed.ncbi.nlm.nih.gov/31118969/
Docherty et al., acute and chronic young-adult trial — MDPI Nutrients — https://www.mdpi.com/2072-6643/15/22/4842
Grozier et al., metabolic flexibility and cognition — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC9762243/
Surendran et al., acute 3 g 10:1 fruiting-body extract trial — PubMed — https://pubmed.ncbi.nlm.nih.gov/40276537/
Cha et al., mushrooms, mood, and neurocognitive health review — ScienceDirect — https://www.sciencedirect.com/science/article/pii/S0149763424000162
Menon et al., lion’s mane supplement systematic review — Frontiers — https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1641246/full
FDA dietary supplements overview — FDA — https://www.fda.gov/food/dietary-supplements
LiverTox lion’s mane safety summary — NCBI Bookshelf — https://www.ncbi.nlm.nih.gov/books/NBK599740/
More from the Supplement Ingredients & Medical Ingredients Encyclopedia
